The SILVER Study: Systolic Hypertension Interaction With Left Ventricular Remodeling
Status:
Completed
Trial end date:
2003-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of ALT-711 in the treatment
of isolated systolic hypertension in a formal study in patients with left ventricular
hypertrophy. Eligible patients will be randomized to double-blind treatment once daily for 6
months with oral ALT-711 (210 mg) or placebo.